Darunavir (TMC114): a new HIV-1 protease inhibitor

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.8, Iss.12, 2007-08, pp. : 1951-1964

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of Darunavir (TMC114) and Atazanavir during Coadministration in HIV-Negative, Healthy Volunteers

By Sekar Vanitha J.

Drugs in R&D, Vol. 8, Iss. 4, 2007-01 ,pp. : 241-248

Adis International

Access to resources Recommend Favorite

Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection

By Robertson Jaime Feinberg Judith

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1363-1375

Informa Healthcare

Access to resources Recommend Favorite

Drug Interactions of Tipranavir, a New HIV Protease Inhibitor

Drug Metabolism Letters, Vol. 1, Iss. 1, 2007-01 ,pp. : 81-84

Bentham Science Publishers

Access to resources Recommend Favorite

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment

By Barragan Patricia Podzamczer Daniel

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2363-2375

Informa Healthcare

Access to resources Recommend Favorite

Dual protease inhibitor therapy in the management of the HIV-1

By Yu K. Daar E.S.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 7, 2000-12 ,pp. : 1331-1342

Informa Healthcare

Access to resources Recommend Favorite